HC Wainwright Issues Optimistic Outlook for JSPR Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Equities researchers at HC Wainwright raised their Q1 2026 EPS estimates for shares of Jasper Therapeutics in a research note issued on Tuesday, March 31st. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.37) for the quarter, up from their prior estimate of ($0.79). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.85) EPS and FY2029 earnings at ($0.78) EPS.

Several other research analysts also recently commented on JSPR. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Thursday, January 22nd. UBS Group started coverage on shares of Jasper Therapeutics in a research report on Monday, March 23rd. They set a “neutral” rating on the stock. Finally, Rodman & Renshaw began coverage on shares of Jasper Therapeutics in a report on Tuesday, January 13th. They issued a “buy” rating and a $17.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $19.88.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock opened at $0.69 on Thursday. Jasper Therapeutics has a 52 week low of $0.69 and a 52 week high of $7.19. The firm has a market capitalization of $19.25 million, a PE ratio of -0.15 and a beta of 3.20. The business’s 50-day simple moving average is $1.28 and its 200-day simple moving average is $1.75.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.47.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors have recently bought and sold shares of the business. Quadrature Capital Ltd bought a new stake in Jasper Therapeutics in the fourth quarter valued at about $123,000. Millennium Management LLC grew its position in Jasper Therapeutics by 194.2% in the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock valued at $1,965,000 after acquiring an additional 708,844 shares during the period. Engineers Gate Manager LP acquired a new position in Jasper Therapeutics during the fourth quarter worth $26,000. Boothbay Fund Management LLC lifted its holdings in shares of Jasper Therapeutics by 79.4% during the fourth quarter. Boothbay Fund Management LLC now owns 793,954 shares of the company’s stock valued at $1,453,000 after acquiring an additional 351,312 shares during the period. Finally, ADAR1 Capital Management LLC bought a new position in shares of Jasper Therapeutics during the fourth quarter valued at $256,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.